Harbinger Research Issues Research Brief for Amazon Biotech Inc
Harbinger Research Issues Research Brief for Amazon Biotech Inc. With a Speculative Buy Rating and Price Target of $0.25
February 16, 2007 -- Harbinger Research LLC, www.harbingerresearch.com, an independent research firm, issued a Research Brief today for Amazon Biotech, Inc. (OTCBB: AMZB), a development stage pharmaceutical/biotech company that is developing an all natural drug (AMZ 0026) for the treatment of HIV/AIDS.
The report provides a description of Amazon Biotech's business, industry, product, strategy, management team, and investment opportunities and risks. The report also includes a rating and price target.
The report is available free of charge at http://www.harbingerresearch.com/viewCompany.php?company=21.
About Harbinger Research, LLC:
Harbinger Research is a quality-leading New York based independent equity research company that provides insightful, in-depth equity research coverage and informational reports to smaller U.S. traded companies and the individuals and institutions that invest in them.
Amazon Biotech Inc.
For further information on Harbinger Research, please visit www.harbingerresearch.com
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: www.amazonbiotech.com.
February 16, 2007 -- Harbinger Research LLC, www.harbingerresearch.com, an independent research firm, issued a Research Brief today for Amazon Biotech, Inc. (OTCBB: AMZB), a development stage pharmaceutical/biotech company that is developing an all natural drug (AMZ 0026) for the treatment of HIV/AIDS.
The report provides a description of Amazon Biotech's business, industry, product, strategy, management team, and investment opportunities and risks. The report also includes a rating and price target.
The report is available free of charge at http://www.harbingerresearch.com/viewCompany.php?company=21.
About Harbinger Research, LLC:
Harbinger Research is a quality-leading New York based independent equity research company that provides insightful, in-depth equity research coverage and informational reports to smaller U.S. traded companies and the individuals and institutions that invest in them.
Amazon Biotech Inc.
For further information on Harbinger Research, please visit www.harbingerresearch.com
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: www.amazonbiotech.com.
posted by Famous Quotations - Harbinger Research Issues Research Brief for Amazon Biotech Inc
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home